GU Cancers 2024 | S1314-COXEN: GMLF models to predict responses in MIBC

Bishoy Faltas, MD, Weill Cornell Medicine, New York, NY, discusses the role of a multi-modal late fusion deep learning model to predict outcomes in the S1314-COXEN trial (NCT02177695) of neoadjuvant chemotherapy in muscle-invasive bladder cancer (MIBC). The model was able to predict chemotherapy response in patients by combining RNA expression data and whole slide images. This interview took place at the ASCO GU Cancers Symposium 2024 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.